Dermal leishmaniasis after kala-azar infection: successful treatment with rifampin.
A patient with dermal leishmaniasis subsequent to kala-azar was treated with sodium stibogluconate, but the condition did not improve. The patient was then treated with rifampin which has not been used to treat this condition in the past. All clinical features cleared spontaneously by six weeks. No overt disease was noted during the next three months. Rifampin can therefore be used to treat post-kala-azar dermal leishmaniasis when standard procedures are ineffective.
D000328:Adult; D006801:Humans; D007896:Leishmaniasis / Q000188:drug therapy* / Q000473:pathology; D007898:Leishmaniasis, Visceral / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D012293:Rifampin / Q000627:therapeutic use*; D012867:Skin / Q000473:pathology
D012293:Rifampin